Developmental outcomes following vaccine-proximate febrile seizures in children.

Adult Australia / epidemiology Case-Control Studies Child Development / drug effects Child, Preschool Cohort Studies Female Follow-Up Studies Humans Infant Male Prospective Studies Seizures, Febrile / chemically induced Vaccines / adverse effects

Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
21 07 2020
Historique:
received: 15 08 2019
accepted: 26 01 2020
pubmed: 3 7 2020
medline: 2 10 2020
entrez: 3 7 2020
Statut: ppublish

Résumé

To compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure. In this prospective multicenter cohort study, children with their first FS before 30 months of age between May 2013 and April 2016 were recruited from 4 Australian pediatric hospitals and classified as having VP-FS or NVP-FS. Similar-aged children with no seizure history were recruited as controls. The Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) was administered to participants with FS 12 to 24 months after their initial FS and to controls 12 to 42 months of age at the time of assessment. The primary outcome was the Bayley-III cognitive score. Children's preacademic skills were assessed with the Woodcock-Johnson Tests of Achievement, Third Edition, and their behavior and executive functioning were obtained from parent questionnaires. There was no significant difference in cognitive function between children with VP-FS (n = 62), those with NVP-FS (n = 70), and controls (n = 90) ( VP-FS was not associated with an increased risk of developmental or behavioral problems in young children compared to children with NVP-FS or controls. Parents and providers should be reassured by the absence of adverse effects of VP-FS on the development of children.

Identifiants

DOI: 10.1212/WNL.0000000000009876 PMID: 32611632
pubmed: 32611632
pii: WNL.0000000000009876
doi: 10.1212/WNL.0000000000009876
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e226-e238

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 American Academy of Neurology.

Auteurs

Lucy Deng (L)

From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia. lucy.deng@health.nsw.gov.au.
ORCID: 0000-0003-0066-2218

Nicholas Wood (N)

From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia.

Kristine Macartney (K)

From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia.

Michael Gold (M)

From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia.

Nigel Crawford (N)

From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia.

Jim Buttery (J)

From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia.

Peter Richmond (P)

From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia.

Belinda Barton (B)

From the National Centre for Immunisation Research and Surveillance (L.D., N.W., K.M.), Children's Hospital Education Research Institute (B.B.), and Kids Neuroscience Centre (B.B.), The Children's Hospital at Westmead; University of Sydney Children's Hospital Westmead Clinical School (L.D., N.W., K.M., B.B.); Discipline of Paediatrics (M.G.), School of Medicine, Women's and Children's Hospital, University of Adelaide; Department of Paediatrics (N.C.), University of Melbourne, Royal Children's Hospital; Murdoch Children's Research Institute (N.C., J.B.), Parkville; Infection and Immunity (J.B.), Monash Children's Hospital, Department of Paediatrics, Monash Centre for Health Care Research and Implementation, Monash University, Clayton; Wesfarmer's Centre of Vaccines and Infectious Disease (P.R.), Telethon Kids Institute, West Perth; and School of Paediatrics and Child Health (P.R.), University of Western Australia, Perth, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Developmental outcomes following...
questionsmedicales.fr › Régions géographiques › Océanie › Australasie › Australie › Developmental outcomes following...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Developmental outcomes following...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Développement humain › Développement de l'enfant › Developmental outcomes following...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Enfant d'âge préscolaire › Developmental outcomes following...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Developmental outcomes following...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Developmental outcomes following...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Developmental outcomes following...
questionsmedicales.fr › Personnes › Tranches d'âge › Nourrisson › Developmental outcomes following...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Developmental outcomes following...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Crises épileptiques › Crises convulsives fébriles › Developmental outcomes following...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Developmental outcomes following...